In Vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates

Cancer Biotherapy and Radiopharmaceuticals

Volumn 16, Issue 2, 2001, Pages 133-146

  Milenic, Diane E ^a   Roselli, Mario ^a   Mirzadeh, Saed ^a   Pippin, C Greg ^a   Gansow, Otto A ^a   Colcher, David ^a   Brechbiel, Martin W ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

a emitters; Bismuth; Chelates; Monoclonal antibody; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BISMUTH 213; BISMUTH DERIVATIVE; MONOCLONAL ANTIBODY B.72.3; PENTETIC ACID DERIVATIVE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; CHELATION; COMPLEX FORMATION; FEMALE; IMMUNOREACTIVITY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; TARGET ORGAN;

EID: 0035707710     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497801300189227     Document Type: Article

References (47)

1. Radioimmunotherapy of malignancies
2. Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy
3. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer
4. Dosimetric aspects of radiolabeled antibodies for tumour therapy
5. 212Bismuth linked to an anti-pancreatic carcinoma antibody: Model for alpha-particle-emitter radioimmunotherapy
6. 212Bi-anti-Tac
7. Improved in vivo stability and tumor targeting of bismuth-labeled antibody
8. B-2E4 is stable in vivo and is a suitable immunoconjugate for testing α-particle-emitting bismuth radionuclides in interleukin-2 receptor targeted immunotherapy
9. Radioimmunotherapy with alpha-emitting nuclides
10. Measuring astatine-211 distribution with SPECT
11. 211At in small volumes for evaluation of targeted radiotherapy in animal models
12. 224Ra
13. Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids: 1,4,7-Triazacyclonoane-N,NN, NO-triacetic acid, 1,4,7,10-tetra-azacyclodecane-N,NN, NO, NNO-tetraacetic acid, and 1,4,8,11-tetra-azacyclo-decane-N,NN, NO,NNO-tetraacetic acid
14. Convenient synthesis of bifunctional tetra-aza macrocycles
15. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy
16. Antibody responses to macrocycles in lymphoma
17. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor imaging studies
18. Backbone-substituted DTPA ligands for radioimmunotherapy with yttrium-90
19. Biodistribution studies of indium- and yttrium-labeled mAb B72.3 using DTPA-derived bifunctional chelates
20. 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts
21. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies
22. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies
23. Monoclonal antibodies: They're more and less than you think
24. 111In-CYT-103)
25. TAG-72 as a tumor marker
26. 4
27. Protein measurement with the folin phenol reagent
28. Synthesis of C-functionalized trans-cyclohexyldiethylene-triamine-pentaacetic acids for labelling of monoclonal antibodies with the bismuth-212 α-article emitter
29. New method for the chelation of Indium- 111 to monoclonal antibodies: Biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts
30. Protein and cell membrane iodinations with a sparingly soluble chloramide 1,3,4,6-terachloro-3a,6a-diphenyl-glycouril
31. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts
32. Radionuclides for radioimmunotherapy: Criteria for selection
33. The feasibility of Ac-225 as a source of α-particles in radioimmunotherapy
34. 225Ac
35. 225Ac for vascular targeted radioimmunotherapy of lung tumors
36. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts
37. Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies
38. Effective α-particle-mediated radioimmunotherapy of murine leukemia
39. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49
40. Rapid tumor penetrance of a single-chain Fv and comparison with other immunoglobulin forms
41. 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model
42. In vivo tumor targeting of a recombinant single-chain antigen-binding protein
43. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities
44. Biologic properties of chimeric CH1 domain-deleted and CH2 domain-deleted anti-carcinoma immunoglobulins
45. A CDR-grafted (humanized) domain-deleted antitumor antibody
46. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules